University of Utah
The purpose of phase I of this clinical trial is to learn the recommended dose of the drugs loncastuximab tesirine and rituximab in participants with post-transplant lymphoproliferative disorders (PTLD). The purpose of phase II of this clinical trial is to learn if the drugs loncastuximab tesirine and rituximab are effective in participants with post-transplant lymphoproliferative disorders (PTLD).
Inclusion Criteria: * Subject aged ≥ 18 years. * Histologically confirmed B-cell PTLD (monomorphic and polymorphic) following solid organ transplantation; with or without EBV association. --Note: Subjects with classic Hodgkin-like PTLD are excluded. * Measurable disease as defined by the 2014 Lugano Classification as assessed by positron-emission tomography (PET)- computed tomography (CT) or by CT or magnetic resonance imaging (MRI) if the tumor is not fluorodeoxyglucose (FDG)-avid on screening * ECOG Performance Status ≤ 2. * Adequate organ function as defined as: * Hematologic: *…
Lonca will be administered by IV at 75µg/kg every 3 weeks (DL1).
Rituximab or rituximab biosimilar will be administered by IV at 375 mg/m2 on Day 1 of every cycle. Lonca will be administered first, followed by rituximab (with a 30 min wait time between the two agents)
Arctuva estimate
Verify or correct the compensation shown for this listing.